TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
-11.22%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$960M
AUM Growth
+$960M
(-24%)
Cap. Flow
-$76.2M
Cap. Flow
% of AUM
-7.94%
Top 10 Holdings %
Top 10 Hldgs %
64.7%
Holding
35
New
2
Increased
6
Reduced
4
Closed
3
Top Buys
| 1 |
ABVX
Abivax
ABVX
|
$65.5M |
| 2 |
Disc Medicine
IRON
|
$21.9M |
| 3 |
Savara
SVRA
|
$9.52M |
| 4 |
EyePoint Pharmaceuticals
EYPT
|
$8.02M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$7.68M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$61.2M |
| 2 |
Geron
GERN
|
$57.4M |
| 3 |
Structure Therapeutics
GPCR
|
$35.5M |
| 4 |
Astria Therapeutics
ATXS
|
$22.9M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$13.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $116M | 12.08% |
3,670,206
+100,000
| +3% | +$3.16M |
|
2
Dyne Therapeutics
DYN
$1.92B
| $93.5M | 9.75% |
2,650,150
| – | – |
|
|
ABVX
3
Abivax
ABVX
$6.12B
| $80.1M | 8.34% |
6,056,596
+4,956,596
| +451% | +$65.5M |
|
|
SLN
4
Silence Therapeutics
SLN
$227M
| $62.6M | 6.53% |
3,295,350
| – | – |
|
5
Cogent Biosciences
COGT
$1.69B
| $58.7M | 6.12% |
6,964,375
+750,000
| +12% | +$6.32M |
|
|
6
Savara
SVRA
$567M
| $49.8M | 5.19% |
12,362,205
+2,362,205
| +24% | +$9.52M |
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $41.8M | 4.36% |
149,283
| – | – |
|
8
Edgewise Therapeutics
EWTX
$1.51B
| $40.9M | 4.27% |
2,272,728
| – | – |
|
9
Keros Therapeutics
KROS
$618M
| $40.2M | 4.19% |
879,344
| – | – |
|
10
Mineralys Therapeutics
MLYS
$1.03B
| $37.3M | 3.88% |
3,185,185
| – | – |
|
11
Ocular Therapeutix
OCUL
$2.12B
| $36.4M | 3.79% |
5,319,148
| – | – |
|
12
Tyra Biosciences
TYRA
$675M
| $31.8M | 3.31% |
1,989,103
| – | – |
|
13
Kura Oncology
KURA
$686M
| $29.3M | 3.06% |
1,423,642
| – | – |
|
|
14
Structure Therapeutics
GPCR
$1.11B
| $27.3M | 2.84% |
694,547
-903,874
| -57% | -$35.5M |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $26.1M | 2.72% |
2,890,816
+850,000
| +42% | +$7.68M |
|
|
16
Astria Therapeutics
ATXS
$349M
| $25.1M | 2.62% |
2,761,861
-2,517,067
| -48% | -$22.9M |
|
|
CMPS
17
Compass Pathways
CMPS
$424M
| $23.3M | 2.43% |
3,858,000
| – | – |
|
18
Soleno Therapeutics
SLNO
$3.6B
| $22.4M | 2.34% |
550,000
| – | – |
|
|
19
Disc Medicine
IRON
$2.07B
| $21.9M | 2.29% |
+486,957
| New | +$21.9M |
|
20
Tourmaline Bio
TRML
$601M
| $19M | 1.98% |
1,477,593
| – | – |
|
21
Tarsus Pharmaceuticals
TARS
$2.47B
| $15.1M | 1.58% |
556,317
-237,512
| -30% | -$6.46M |
|
22
Adverum Biotechnologies
ADVM
$64.6M
| $13.8M | 1.44% |
2,008,340
| – | – |
|
23
VistaGen Therapeutics
VTGN
$102M
| $9.31M | 0.97% |
2,676,580
| – | – |
|
24
Entrada Therapeutics
TRDA
$208M
| $8.34M | 0.87% |
584,955
| – | – |
|
|
25
EyePoint Pharmaceuticals
EYPT
$797M
| $8.02M | 0.84% |
+922,335
| New | +$8.02M |
|